Details for New Drug Application (NDA): 022569
✉ Email this page to a colleague
The generic ingredient in LAZANDA is fentanyl citrate. There are thirty-one drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the fentanyl citrate profile page.
Summary for 022569
Tradename: | LAZANDA |
Applicant: | Btcp Pharma |
Ingredient: | fentanyl citrate |
Patents: | 5 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY, METERED;NASAL | Strength | EQ 0.1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jun 30, 2011 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Oct 3, 2024 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | ||||||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Jan 16, 2024 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | ||||||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Jan 8, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 022569
Complete Access Available with Subscription